nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—liver cancer—primary biliary cirrhosis	0.447	1	CtDrD
Sorafenib—ABCC2—primary biliary cirrhosis	0.111	0.531	CbGaD
Sorafenib—ABCG2—primary biliary cirrhosis	0.0979	0.469	CbGaD
Sorafenib—ABCC4—Ursodeoxycholic acid—primary biliary cirrhosis	0.0702	0.388	CbGbCtD
Sorafenib—ABCC2—Ursodeoxycholic acid—primary biliary cirrhosis	0.0418	0.231	CbGbCtD
Sorafenib—CYP2B6—Colchicine—primary biliary cirrhosis	0.0186	0.103	CbGbCtD
Sorafenib—CYP2C8—Colchicine—primary biliary cirrhosis	0.0141	0.0777	CbGbCtD
Sorafenib—CYP3A4—Chenodeoxycholic acid—primary biliary cirrhosis	0.0113	0.0624	CbGbCtD
Sorafenib—CYP2C9—Colchicine—primary biliary cirrhosis	0.00981	0.0542	CbGbCtD
Sorafenib—ABCB1—Colchicine—primary biliary cirrhosis	0.00952	0.0526	CbGbCtD
Sorafenib—ABCC2—bile canaliculus—primary biliary cirrhosis	0.00785	0.227	CbGeAlD
Sorafenib—CYP3A4—Colchicine—primary biliary cirrhosis	0.0057	0.0315	CbGbCtD
Sorafenib—ABCC2—bile duct—primary biliary cirrhosis	0.00245	0.071	CbGeAlD
Sorafenib—ABCC2—bile—primary biliary cirrhosis	0.00189	0.0545	CbGeAlD
Sorafenib—Interstitial pneumonia—Chenodeoxycholic acid—primary biliary cirrhosis	0.00114	0.019	CcSEcCtD
Sorafenib—Interstitial pneumonia—Ursodeoxycholic acid—primary biliary cirrhosis	0.00114	0.019	CcSEcCtD
Sorafenib—Gastrointestinal symptom NOS—Colchicine—primary biliary cirrhosis	0.00105	0.0174	CcSEcCtD
Sorafenib—Cholecystitis—Ursodeoxycholic acid—primary biliary cirrhosis	0.000962	0.016	CcSEcCtD
Sorafenib—Cholecystitis—Chenodeoxycholic acid—primary biliary cirrhosis	0.000962	0.016	CcSEcCtD
Sorafenib—Hypothyroidism—Colchicine—primary biliary cirrhosis	0.000957	0.0159	CcSEcCtD
Sorafenib—PDGFRA—gall bladder—primary biliary cirrhosis	0.00087	0.0252	CbGeAlD
Sorafenib—Regorafenib—ABCG2—primary biliary cirrhosis	0.000832	0.468	CrCbGaD
Sorafenib—Interstitial lung disease—Ursodeoxycholic acid—primary biliary cirrhosis	0.00078	0.013	CcSEcCtD
Sorafenib—Interstitial lung disease—Chenodeoxycholic acid—primary biliary cirrhosis	0.00078	0.013	CcSEcCtD
Sorafenib—TIE1—epithelium—primary biliary cirrhosis	0.000747	0.0216	CbGeAlD
Sorafenib—Pleural effusion—Ursodeoxycholic acid—primary biliary cirrhosis	0.000721	0.012	CcSEcCtD
Sorafenib—Pleural effusion—Chenodeoxycholic acid—primary biliary cirrhosis	0.000721	0.012	CcSEcCtD
Sorafenib—TIE1—smooth muscle tissue—primary biliary cirrhosis	0.00072	0.0208	CbGeAlD
Sorafenib—KIT—gall bladder—primary biliary cirrhosis	0.000695	0.0201	CbGeAlD
Sorafenib—Rhabdomyolysis—Colchicine—primary biliary cirrhosis	0.000695	0.0116	CcSEcCtD
Sorafenib—PDGFRB—gall bladder—primary biliary cirrhosis	0.000679	0.0196	CbGeAlD
Sorafenib—Vismodegib—ABCG2—primary biliary cirrhosis	0.00066	0.371	CrCbGaD
Sorafenib—FLT4—epithelium—primary biliary cirrhosis	0.000617	0.0179	CbGeAlD
Sorafenib—Bone disorder—Ursodeoxycholic acid—primary biliary cirrhosis	0.000611	0.0102	CcSEcCtD
Sorafenib—Bone disorder—Chenodeoxycholic acid—primary biliary cirrhosis	0.000611	0.0102	CcSEcCtD
Sorafenib—Drug interaction—Chenodeoxycholic acid—primary biliary cirrhosis	0.000595	0.0099	CcSEcCtD
Sorafenib—Drug interaction—Ursodeoxycholic acid—primary biliary cirrhosis	0.000595	0.0099	CcSEcCtD
Sorafenib—Blood bilirubin increased—Ursodeoxycholic acid—primary biliary cirrhosis	0.000584	0.00971	CcSEcCtD
Sorafenib—Blood bilirubin increased—Chenodeoxycholic acid—primary biliary cirrhosis	0.000584	0.00971	CcSEcCtD
Sorafenib—MKNK2—epithelium—primary biliary cirrhosis	0.000559	0.0162	CbGeAlD
Sorafenib—MAP3K7—smooth muscle tissue—primary biliary cirrhosis	0.000556	0.0161	CbGeAlD
Sorafenib—RET—epithelium—primary biliary cirrhosis	0.000545	0.0158	CbGeAlD
Sorafenib—MKNK2—smooth muscle tissue—primary biliary cirrhosis	0.000539	0.0156	CbGeAlD
Sorafenib—Influenza like illness—Ursodeoxycholic acid—primary biliary cirrhosis	0.000536	0.00892	CcSEcCtD
Sorafenib—Influenza like illness—Chenodeoxycholic acid—primary biliary cirrhosis	0.000536	0.00892	CcSEcCtD
Sorafenib—CDK7—liver—primary biliary cirrhosis	0.000536	0.0155	CbGeAlD
Sorafenib—TAOK2—liver—primary biliary cirrhosis	0.000532	0.0154	CbGeAlD
Sorafenib—Hepatic function abnormal—Colchicine—primary biliary cirrhosis	0.000511	0.00849	CcSEcCtD
Sorafenib—Neoplasm—Ursodeoxycholic acid—primary biliary cirrhosis	0.000499	0.0083	CcSEcCtD
Sorafenib—Neoplasm—Chenodeoxycholic acid—primary biliary cirrhosis	0.000499	0.0083	CcSEcCtD
Sorafenib—RALBP1—smooth muscle tissue—primary biliary cirrhosis	0.000486	0.0141	CbGeAlD
Sorafenib—FLT1—epithelium—primary biliary cirrhosis	0.00048	0.0139	CbGeAlD
Sorafenib—RAF1—epithelium—primary biliary cirrhosis	0.000477	0.0138	CbGeAlD
Sorafenib—ZAK—liver—primary biliary cirrhosis	0.000463	0.0134	CbGeAlD
Sorafenib—FLT1—smooth muscle tissue—primary biliary cirrhosis	0.000463	0.0134	CbGeAlD
Sorafenib—RAF1—smooth muscle tissue—primary biliary cirrhosis	0.00046	0.0133	CbGeAlD
Sorafenib—Hepatic function abnormal—Chenodeoxycholic acid—primary biliary cirrhosis	0.000459	0.00763	CcSEcCtD
Sorafenib—Hepatic function abnormal—Ursodeoxycholic acid—primary biliary cirrhosis	0.000459	0.00763	CcSEcCtD
Sorafenib—HIPK3—liver—primary biliary cirrhosis	0.000453	0.0131	CbGeAlD
Sorafenib—Cardiac failure congestive—Chenodeoxycholic acid—primary biliary cirrhosis	0.000442	0.00735	CcSEcCtD
Sorafenib—Cardiac failure congestive—Ursodeoxycholic acid—primary biliary cirrhosis	0.000442	0.00735	CcSEcCtD
Sorafenib—PDGFRA—smooth muscle tissue—primary biliary cirrhosis	0.000434	0.0125	CbGeAlD
Sorafenib—TIE1—liver—primary biliary cirrhosis	0.000424	0.0123	CbGeAlD
Sorafenib—Dehydration—Colchicine—primary biliary cirrhosis	0.000415	0.0069	CcSEcCtD
Sorafenib—Cardiac failure—Chenodeoxycholic acid—primary biliary cirrhosis	0.000411	0.00683	CcSEcCtD
Sorafenib—Cardiac failure—Ursodeoxycholic acid—primary biliary cirrhosis	0.000411	0.00683	CcSEcCtD
Sorafenib—BRAF—liver—primary biliary cirrhosis	0.000406	0.0117	CbGeAlD
Sorafenib—KDR—epithelium—primary biliary cirrhosis	0.000406	0.0117	CbGeAlD
Sorafenib—Aspartate aminotransferase increased—Colchicine—primary biliary cirrhosis	0.000402	0.00668	CcSEcCtD
Sorafenib—Alanine aminotransferase increased—Colchicine—primary biliary cirrhosis	0.000393	0.00654	CcSEcCtD
Sorafenib—KDR—smooth muscle tissue—primary biliary cirrhosis	0.000391	0.0113	CbGeAlD
Sorafenib—EPHX2—liver—primary biliary cirrhosis	0.000388	0.0112	CbGeAlD
Sorafenib—FLT3—liver—primary biliary cirrhosis	0.000385	0.0111	CbGeAlD
Sorafenib—CSF1R—smooth muscle tissue—primary biliary cirrhosis	0.000382	0.011	CbGeAlD
Sorafenib—Dehydration—Chenodeoxycholic acid—primary biliary cirrhosis	0.000373	0.0062	CcSEcCtD
Sorafenib—Dehydration—Ursodeoxycholic acid—primary biliary cirrhosis	0.000373	0.0062	CcSEcCtD
Sorafenib—Abdominal discomfort—Colchicine—primary biliary cirrhosis	0.00037	0.00615	CcSEcCtD
Sorafenib—Abdominal pain upper—Ursodeoxycholic acid—primary biliary cirrhosis	0.000366	0.00609	CcSEcCtD
Sorafenib—Abdominal pain upper—Chenodeoxycholic acid—primary biliary cirrhosis	0.000366	0.00609	CcSEcCtD
Sorafenib—Breast disorder—Chenodeoxycholic acid—primary biliary cirrhosis	0.000362	0.00602	CcSEcCtD
Sorafenib—Breast disorder—Ursodeoxycholic acid—primary biliary cirrhosis	0.000362	0.00602	CcSEcCtD
Sorafenib—Aspartate aminotransferase increased—Chenodeoxycholic acid—primary biliary cirrhosis	0.000361	0.006	CcSEcCtD
Sorafenib—Aspartate aminotransferase increased—Ursodeoxycholic acid—primary biliary cirrhosis	0.000361	0.006	CcSEcCtD
Sorafenib—Neutropenia—Colchicine—primary biliary cirrhosis	0.000361	0.006	CcSEcCtD
Sorafenib—KIT—epithelium—primary biliary cirrhosis	0.00036	0.0104	CbGeAlD
Sorafenib—UGT1A9—liver—primary biliary cirrhosis	0.000355	0.0103	CbGeAlD
Sorafenib—Gastritis—Ursodeoxycholic acid—primary biliary cirrhosis	0.000355	0.0059	CcSEcCtD
Sorafenib—Gastritis—Chenodeoxycholic acid—primary biliary cirrhosis	0.000355	0.0059	CcSEcCtD
Sorafenib—Alanine aminotransferase increased—Chenodeoxycholic acid—primary biliary cirrhosis	0.000354	0.00588	CcSEcCtD
Sorafenib—Alanine aminotransferase increased—Ursodeoxycholic acid—primary biliary cirrhosis	0.000354	0.00588	CcSEcCtD
Sorafenib—PDGFRB—epithelium—primary biliary cirrhosis	0.000351	0.0102	CbGeAlD
Sorafenib—FLT4—liver—primary biliary cirrhosis	0.00035	0.0101	CbGeAlD
Sorafenib—KIT—smooth muscle tissue—primary biliary cirrhosis	0.000347	0.01	CbGeAlD
Sorafenib—Dysphagia—Chenodeoxycholic acid—primary biliary cirrhosis	0.000346	0.00576	CcSEcCtD
Sorafenib—Dysphagia—Ursodeoxycholic acid—primary biliary cirrhosis	0.000346	0.00576	CcSEcCtD
Sorafenib—FGFR1—liver—primary biliary cirrhosis	0.000345	0.00999	CbGeAlD
Sorafenib—Pancreatitis—Chenodeoxycholic acid—primary biliary cirrhosis	0.00034	0.00565	CcSEcCtD
Sorafenib—Pancreatitis—Ursodeoxycholic acid—primary biliary cirrhosis	0.00034	0.00565	CcSEcCtD
Sorafenib—PDGFRB—smooth muscle tissue—primary biliary cirrhosis	0.000338	0.00979	CbGeAlD
Sorafenib—Neuropathy peripheral—Colchicine—primary biliary cirrhosis	0.000337	0.00561	CcSEcCtD
Sorafenib—Stomatitis—Colchicine—primary biliary cirrhosis	0.000335	0.00557	CcSEcCtD
Sorafenib—Abdominal discomfort—Chenodeoxycholic acid—primary biliary cirrhosis	0.000332	0.00552	CcSEcCtD
Sorafenib—Abdominal discomfort—Ursodeoxycholic acid—primary biliary cirrhosis	0.000332	0.00552	CcSEcCtD
Sorafenib—MAP3K7—liver—primary biliary cirrhosis	0.000327	0.00946	CbGeAlD
Sorafenib—MKNK2—liver—primary biliary cirrhosis	0.000317	0.00916	CbGeAlD
Sorafenib—Weight decreased—Ursodeoxycholic acid—primary biliary cirrhosis	0.000313	0.00521	CcSEcCtD
Sorafenib—Weight decreased—Chenodeoxycholic acid—primary biliary cirrhosis	0.000313	0.00521	CcSEcCtD
Sorafenib—MKNK1—liver—primary biliary cirrhosis	0.000313	0.00905	CbGeAlD
Sorafenib—Pneumonia—Ursodeoxycholic acid—primary biliary cirrhosis	0.000311	0.00517	CcSEcCtD
Sorafenib—Pneumonia—Chenodeoxycholic acid—primary biliary cirrhosis	0.000311	0.00517	CcSEcCtD
Sorafenib—Infestation—Ursodeoxycholic acid—primary biliary cirrhosis	0.000309	0.00514	CcSEcCtD
Sorafenib—Infestation—Chenodeoxycholic acid—primary biliary cirrhosis	0.000309	0.00514	CcSEcCtD
Sorafenib—Infestation NOS—Chenodeoxycholic acid—primary biliary cirrhosis	0.000309	0.00514	CcSEcCtD
Sorafenib—Infestation NOS—Ursodeoxycholic acid—primary biliary cirrhosis	0.000309	0.00514	CcSEcCtD
Sorafenib—Acute coronary syndrome—Ursodeoxycholic acid—primary biliary cirrhosis	0.000305	0.00506	CcSEcCtD
Sorafenib—Acute coronary syndrome—Chenodeoxycholic acid—primary biliary cirrhosis	0.000305	0.00506	CcSEcCtD
Sorafenib—Renal failure—Chenodeoxycholic acid—primary biliary cirrhosis	0.000304	0.00505	CcSEcCtD
Sorafenib—Renal failure—Ursodeoxycholic acid—primary biliary cirrhosis	0.000304	0.00505	CcSEcCtD
Sorafenib—Myocardial infarction—Ursodeoxycholic acid—primary biliary cirrhosis	0.000303	0.00504	CcSEcCtD
Sorafenib—Myocardial infarction—Chenodeoxycholic acid—primary biliary cirrhosis	0.000303	0.00504	CcSEcCtD
Sorafenib—Jaundice—Ursodeoxycholic acid—primary biliary cirrhosis	0.000301	0.00501	CcSEcCtD
Sorafenib—Jaundice—Chenodeoxycholic acid—primary biliary cirrhosis	0.000301	0.00501	CcSEcCtD
Sorafenib—CYP3A7—liver—primary biliary cirrhosis	0.000295	0.00854	CbGeAlD
Sorafenib—Hepatobiliary disease—Chenodeoxycholic acid—primary biliary cirrhosis	0.000292	0.00486	CcSEcCtD
Sorafenib—Hepatobiliary disease—Ursodeoxycholic acid—primary biliary cirrhosis	0.000292	0.00486	CcSEcCtD
Sorafenib—Epistaxis—Ursodeoxycholic acid—primary biliary cirrhosis	0.000291	0.00485	CcSEcCtD
Sorafenib—Epistaxis—Chenodeoxycholic acid—primary biliary cirrhosis	0.000291	0.00485	CcSEcCtD
Sorafenib—Vismodegib—ALB—primary biliary cirrhosis	0.000288	0.162	CrCbGaD
Sorafenib—RALBP1—liver—primary biliary cirrhosis	0.000286	0.00828	CbGeAlD
Sorafenib—Haemoglobin—Chenodeoxycholic acid—primary biliary cirrhosis	0.000279	0.00464	CcSEcCtD
Sorafenib—Haemoglobin—Ursodeoxycholic acid—primary biliary cirrhosis	0.000279	0.00464	CcSEcCtD
Sorafenib—Mediastinal disorder—Colchicine—primary biliary cirrhosis	0.000278	0.00463	CcSEcCtD
Sorafenib—Haemorrhage—Ursodeoxycholic acid—primary biliary cirrhosis	0.000277	0.00461	CcSEcCtD
Sorafenib—Haemorrhage—Chenodeoxycholic acid—primary biliary cirrhosis	0.000277	0.00461	CcSEcCtD
Sorafenib—Urinary tract disorder—Ursodeoxycholic acid—primary biliary cirrhosis	0.000274	0.00455	CcSEcCtD
Sorafenib—Urinary tract disorder—Chenodeoxycholic acid—primary biliary cirrhosis	0.000274	0.00455	CcSEcCtD
Sorafenib—Alopecia—Colchicine—primary biliary cirrhosis	0.000273	0.00454	CcSEcCtD
Sorafenib—Connective tissue disorder—Ursodeoxycholic acid—primary biliary cirrhosis	0.000273	0.00453	CcSEcCtD
Sorafenib—Connective tissue disorder—Chenodeoxycholic acid—primary biliary cirrhosis	0.000273	0.00453	CcSEcCtD
Sorafenib—FLT1—liver—primary biliary cirrhosis	0.000272	0.00787	CbGeAlD
Sorafenib—Urethral disorder—Chenodeoxycholic acid—primary biliary cirrhosis	0.000272	0.00452	CcSEcCtD
Sorafenib—Urethral disorder—Ursodeoxycholic acid—primary biliary cirrhosis	0.000272	0.00452	CcSEcCtD
Sorafenib—RAF1—liver—primary biliary cirrhosis	0.000271	0.00783	CbGeAlD
Sorafenib—Malnutrition—Colchicine—primary biliary cirrhosis	0.000269	0.00447	CcSEcCtD
Sorafenib—HTR2B—smooth muscle tissue—primary biliary cirrhosis	0.000268	0.00776	CbGeAlD
Sorafenib—Tinnitus—Ursodeoxycholic acid—primary biliary cirrhosis	0.000259	0.0043	CcSEcCtD
Sorafenib—Tinnitus—Chenodeoxycholic acid—primary biliary cirrhosis	0.000259	0.0043	CcSEcCtD
Sorafenib—Muscle spasms—Colchicine—primary biliary cirrhosis	0.000258	0.0043	CcSEcCtD
Sorafenib—STK10—liver—primary biliary cirrhosis	0.000258	0.00745	CbGeAlD
Sorafenib—Cardiac disorder—Chenodeoxycholic acid—primary biliary cirrhosis	0.000257	0.00428	CcSEcCtD
Sorafenib—Cardiac disorder—Ursodeoxycholic acid—primary biliary cirrhosis	0.000257	0.00428	CcSEcCtD
Sorafenib—PDGFRA—liver—primary biliary cirrhosis	0.000255	0.00738	CbGeAlD
Sorafenib—Angiopathy—Chenodeoxycholic acid—primary biliary cirrhosis	0.000252	0.00418	CcSEcCtD
Sorafenib—Angiopathy—Ursodeoxycholic acid—primary biliary cirrhosis	0.000252	0.00418	CcSEcCtD
Sorafenib—CYP3A7-CYP3A51P—liver—primary biliary cirrhosis	0.000251	0.00726	CbGeAlD
Sorafenib—Immune system disorder—Ursodeoxycholic acid—primary biliary cirrhosis	0.00025	0.00417	CcSEcCtD
Sorafenib—Immune system disorder—Chenodeoxycholic acid—primary biliary cirrhosis	0.00025	0.00417	CcSEcCtD
Sorafenib—Mediastinal disorder—Ursodeoxycholic acid—primary biliary cirrhosis	0.00025	0.00416	CcSEcCtD
Sorafenib—Mediastinal disorder—Chenodeoxycholic acid—primary biliary cirrhosis	0.00025	0.00416	CcSEcCtD
Sorafenib—Anaemia—Colchicine—primary biliary cirrhosis	0.000248	0.00413	CcSEcCtD
Sorafenib—Arrhythmia—Ursodeoxycholic acid—primary biliary cirrhosis	0.000248	0.00412	CcSEcCtD
Sorafenib—Arrhythmia—Chenodeoxycholic acid—primary biliary cirrhosis	0.000248	0.00412	CcSEcCtD
Sorafenib—Angioedema—Colchicine—primary biliary cirrhosis	0.000246	0.00408	CcSEcCtD
Sorafenib—Alopecia—Chenodeoxycholic acid—primary biliary cirrhosis	0.000245	0.00408	CcSEcCtD
Sorafenib—Alopecia—Ursodeoxycholic acid—primary biliary cirrhosis	0.000245	0.00408	CcSEcCtD
Sorafenib—UGT1A1—liver—primary biliary cirrhosis	0.000243	0.00704	CbGeAlD
Sorafenib—Malnutrition—Ursodeoxycholic acid—primary biliary cirrhosis	0.000241	0.00402	CcSEcCtD
Sorafenib—Malnutrition—Chenodeoxycholic acid—primary biliary cirrhosis	0.000241	0.00402	CcSEcCtD
Sorafenib—Leukopenia—Colchicine—primary biliary cirrhosis	0.000241	0.004	CcSEcCtD
Sorafenib—Muscle spasms—Chenodeoxycholic acid—primary biliary cirrhosis	0.000232	0.00386	CcSEcCtD
Sorafenib—Muscle spasms—Ursodeoxycholic acid—primary biliary cirrhosis	0.000232	0.00386	CcSEcCtD
Sorafenib—KDR—liver—primary biliary cirrhosis	0.00023	0.00665	CbGeAlD
Sorafenib—MAP2K5—liver—primary biliary cirrhosis	0.00023	0.00665	CbGeAlD
Sorafenib—Arthralgia—Colchicine—primary biliary cirrhosis	0.000229	0.0038	CcSEcCtD
Sorafenib—Myalgia—Colchicine—primary biliary cirrhosis	0.000229	0.0038	CcSEcCtD
Sorafenib—CSF1R—liver—primary biliary cirrhosis	0.000224	0.00649	CbGeAlD
Sorafenib—Anaemia—Chenodeoxycholic acid—primary biliary cirrhosis	0.000223	0.00371	CcSEcCtD
Sorafenib—Anaemia—Ursodeoxycholic acid—primary biliary cirrhosis	0.000223	0.00371	CcSEcCtD
Sorafenib—Angioedema—Ursodeoxycholic acid—primary biliary cirrhosis	0.000221	0.00367	CcSEcCtD
Sorafenib—Angioedema—Chenodeoxycholic acid—primary biliary cirrhosis	0.000221	0.00367	CcSEcCtD
Sorafenib—Syncope—Ursodeoxycholic acid—primary biliary cirrhosis	0.000216	0.0036	CcSEcCtD
Sorafenib—Syncope—Chenodeoxycholic acid—primary biliary cirrhosis	0.000216	0.0036	CcSEcCtD
Sorafenib—Leukopenia—Chenodeoxycholic acid—primary biliary cirrhosis	0.000216	0.00359	CcSEcCtD
Sorafenib—Leukopenia—Ursodeoxycholic acid—primary biliary cirrhosis	0.000216	0.00359	CcSEcCtD
Sorafenib—Shock—Colchicine—primary biliary cirrhosis	0.000216	0.00359	CcSEcCtD
Sorafenib—Nervous system disorder—Colchicine—primary biliary cirrhosis	0.000215	0.00358	CcSEcCtD
Sorafenib—Thrombocytopenia—Colchicine—primary biliary cirrhosis	0.000215	0.00357	CcSEcCtD
Sorafenib—Skin disorder—Colchicine—primary biliary cirrhosis	0.000213	0.00354	CcSEcCtD
Sorafenib—Loss of consciousness—Ursodeoxycholic acid—primary biliary cirrhosis	0.000212	0.00353	CcSEcCtD
Sorafenib—Loss of consciousness—Chenodeoxycholic acid—primary biliary cirrhosis	0.000212	0.00353	CcSEcCtD
Sorafenib—Cough—Ursodeoxycholic acid—primary biliary cirrhosis	0.000211	0.0035	CcSEcCtD
Sorafenib—Cough—Chenodeoxycholic acid—primary biliary cirrhosis	0.000211	0.0035	CcSEcCtD
Sorafenib—Hypertension—Ursodeoxycholic acid—primary biliary cirrhosis	0.000208	0.00347	CcSEcCtD
Sorafenib—Hypertension—Chenodeoxycholic acid—primary biliary cirrhosis	0.000208	0.00347	CcSEcCtD
Sorafenib—Arthralgia—Ursodeoxycholic acid—primary biliary cirrhosis	0.000206	0.00342	CcSEcCtD
Sorafenib—Myalgia—Ursodeoxycholic acid—primary biliary cirrhosis	0.000206	0.00342	CcSEcCtD
Sorafenib—Myalgia—Chenodeoxycholic acid—primary biliary cirrhosis	0.000206	0.00342	CcSEcCtD
Sorafenib—Arthralgia—Chenodeoxycholic acid—primary biliary cirrhosis	0.000206	0.00342	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Ursodeoxycholic acid—primary biliary cirrhosis	0.000204	0.00339	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Chenodeoxycholic acid—primary biliary cirrhosis	0.000204	0.00339	CcSEcCtD
Sorafenib—KIT—liver—primary biliary cirrhosis	0.000204	0.0059	CbGeAlD
Sorafenib—Dry mouth—Ursodeoxycholic acid—primary biliary cirrhosis	0.000201	0.00334	CcSEcCtD
Sorafenib—Dry mouth—Chenodeoxycholic acid—primary biliary cirrhosis	0.000201	0.00334	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Colchicine—primary biliary cirrhosis	0.0002	0.00332	CcSEcCtD
Sorafenib—PDGFRB—liver—primary biliary cirrhosis	0.000199	0.00576	CbGeAlD
Sorafenib—Infection—Chenodeoxycholic acid—primary biliary cirrhosis	0.000196	0.00326	CcSEcCtD
Sorafenib—Infection—Ursodeoxycholic acid—primary biliary cirrhosis	0.000196	0.00326	CcSEcCtD
Sorafenib—Shock—Chenodeoxycholic acid—primary biliary cirrhosis	0.000194	0.00322	CcSEcCtD
Sorafenib—Shock—Ursodeoxycholic acid—primary biliary cirrhosis	0.000194	0.00322	CcSEcCtD
Sorafenib—Nervous system disorder—Ursodeoxycholic acid—primary biliary cirrhosis	0.000193	0.00321	CcSEcCtD
Sorafenib—Nervous system disorder—Chenodeoxycholic acid—primary biliary cirrhosis	0.000193	0.00321	CcSEcCtD
Sorafenib—Thrombocytopenia—Chenodeoxycholic acid—primary biliary cirrhosis	0.000193	0.00321	CcSEcCtD
Sorafenib—Thrombocytopenia—Ursodeoxycholic acid—primary biliary cirrhosis	0.000193	0.00321	CcSEcCtD
Sorafenib—Skin disorder—Chenodeoxycholic acid—primary biliary cirrhosis	0.000191	0.00318	CcSEcCtD
Sorafenib—Skin disorder—Ursodeoxycholic acid—primary biliary cirrhosis	0.000191	0.00318	CcSEcCtD
Sorafenib—Decreased appetite—Colchicine—primary biliary cirrhosis	0.000191	0.00317	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Colchicine—primary biliary cirrhosis	0.000189	0.00315	CcSEcCtD
Sorafenib—Fatigue—Colchicine—primary biliary cirrhosis	0.000189	0.00314	CcSEcCtD
Sorafenib—Anorexia—Chenodeoxycholic acid—primary biliary cirrhosis	0.000188	0.00312	CcSEcCtD
Sorafenib—Anorexia—Ursodeoxycholic acid—primary biliary cirrhosis	0.000188	0.00312	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Ursodeoxycholic acid—primary biliary cirrhosis	0.00018	0.00299	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Chenodeoxycholic acid—primary biliary cirrhosis	0.00018	0.00299	CcSEcCtD
Sorafenib—Gastrointestinal pain—Colchicine—primary biliary cirrhosis	0.000179	0.00298	CcSEcCtD
Sorafenib—Dyspnoea—Chenodeoxycholic acid—primary biliary cirrhosis	0.000176	0.00292	CcSEcCtD
Sorafenib—Dyspnoea—Ursodeoxycholic acid—primary biliary cirrhosis	0.000176	0.00292	CcSEcCtD
Sorafenib—Urticaria—Colchicine—primary biliary cirrhosis	0.000174	0.0029	CcSEcCtD
Sorafenib—Dyspepsia—Chenodeoxycholic acid—primary biliary cirrhosis	0.000173	0.00288	CcSEcCtD
Sorafenib—Dyspepsia—Ursodeoxycholic acid—primary biliary cirrhosis	0.000173	0.00288	CcSEcCtD
Sorafenib—Abdominal pain—Colchicine—primary biliary cirrhosis	0.000173	0.00288	CcSEcCtD
Sorafenib—Decreased appetite—Ursodeoxycholic acid—primary biliary cirrhosis	0.000171	0.00285	CcSEcCtD
Sorafenib—Decreased appetite—Chenodeoxycholic acid—primary biliary cirrhosis	0.000171	0.00285	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Chenodeoxycholic acid—primary biliary cirrhosis	0.00017	0.00283	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Ursodeoxycholic acid—primary biliary cirrhosis	0.00017	0.00283	CcSEcCtD
Sorafenib—Fatigue—Ursodeoxycholic acid—primary biliary cirrhosis	0.00017	0.00283	CcSEcCtD
Sorafenib—Fatigue—Chenodeoxycholic acid—primary biliary cirrhosis	0.00017	0.00283	CcSEcCtD
Sorafenib—Pain—Ursodeoxycholic acid—primary biliary cirrhosis	0.000168	0.0028	CcSEcCtD
Sorafenib—Pain—Chenodeoxycholic acid—primary biliary cirrhosis	0.000168	0.0028	CcSEcCtD
Sorafenib—Constipation—Ursodeoxycholic acid—primary biliary cirrhosis	0.000168	0.0028	CcSEcCtD
Sorafenib—Constipation—Chenodeoxycholic acid—primary biliary cirrhosis	0.000168	0.0028	CcSEcCtD
Sorafenib—Hypersensitivity—Colchicine—primary biliary cirrhosis	0.000162	0.00269	CcSEcCtD
Sorafenib—Gastrointestinal pain—Ursodeoxycholic acid—primary biliary cirrhosis	0.000161	0.00268	CcSEcCtD
Sorafenib—Gastrointestinal pain—Chenodeoxycholic acid—primary biliary cirrhosis	0.000161	0.00268	CcSEcCtD
Sorafenib—ABCC4—liver—primary biliary cirrhosis	0.000159	0.00459	CbGeAlD
Sorafenib—Asthenia—Colchicine—primary biliary cirrhosis	0.000157	0.00262	CcSEcCtD
Sorafenib—Urticaria—Ursodeoxycholic acid—primary biliary cirrhosis	0.000157	0.0026	CcSEcCtD
Sorafenib—Urticaria—Chenodeoxycholic acid—primary biliary cirrhosis	0.000157	0.0026	CcSEcCtD
Sorafenib—Abdominal pain—Ursodeoxycholic acid—primary biliary cirrhosis	0.000156	0.00259	CcSEcCtD
Sorafenib—Body temperature increased—Chenodeoxycholic acid—primary biliary cirrhosis	0.000156	0.00259	CcSEcCtD
Sorafenib—Abdominal pain—Chenodeoxycholic acid—primary biliary cirrhosis	0.000156	0.00259	CcSEcCtD
Sorafenib—Body temperature increased—Ursodeoxycholic acid—primary biliary cirrhosis	0.000156	0.00259	CcSEcCtD
Sorafenib—ABCC2—liver—primary biliary cirrhosis	0.000153	0.00444	CbGeAlD
Sorafenib—Diarrhoea—Colchicine—primary biliary cirrhosis	0.00015	0.0025	CcSEcCtD
Sorafenib—Hypersensitivity—Chenodeoxycholic acid—primary biliary cirrhosis	0.000145	0.00241	CcSEcCtD
Sorafenib—Hypersensitivity—Ursodeoxycholic acid—primary biliary cirrhosis	0.000145	0.00241	CcSEcCtD
Sorafenib—Asthenia—Chenodeoxycholic acid—primary biliary cirrhosis	0.000141	0.00235	CcSEcCtD
Sorafenib—Asthenia—Ursodeoxycholic acid—primary biliary cirrhosis	0.000141	0.00235	CcSEcCtD
Sorafenib—Vomiting—Colchicine—primary biliary cirrhosis	0.000139	0.00232	CcSEcCtD
Sorafenib—Pruritus—Ursodeoxycholic acid—primary biliary cirrhosis	0.000139	0.00232	CcSEcCtD
Sorafenib—Pruritus—Chenodeoxycholic acid—primary biliary cirrhosis	0.000139	0.00232	CcSEcCtD
Sorafenib—Rash—Colchicine—primary biliary cirrhosis	0.000138	0.0023	CcSEcCtD
Sorafenib—Dermatitis—Colchicine—primary biliary cirrhosis	0.000138	0.0023	CcSEcCtD
Sorafenib—Headache—Colchicine—primary biliary cirrhosis	0.000137	0.00228	CcSEcCtD
Sorafenib—Diarrhoea—Chenodeoxycholic acid—primary biliary cirrhosis	0.000135	0.00224	CcSEcCtD
Sorafenib—Diarrhoea—Ursodeoxycholic acid—primary biliary cirrhosis	0.000135	0.00224	CcSEcCtD
Sorafenib—CYP2C19—liver—primary biliary cirrhosis	0.000132	0.00381	CbGeAlD
Sorafenib—Dizziness—Chenodeoxycholic acid—primary biliary cirrhosis	0.00013	0.00217	CcSEcCtD
Sorafenib—Dizziness—Ursodeoxycholic acid—primary biliary cirrhosis	0.00013	0.00217	CcSEcCtD
Sorafenib—Nausea—Colchicine—primary biliary cirrhosis	0.00013	0.00217	CcSEcCtD
Sorafenib—Vomiting—Chenodeoxycholic acid—primary biliary cirrhosis	0.000125	0.00208	CcSEcCtD
Sorafenib—Vomiting—Ursodeoxycholic acid—primary biliary cirrhosis	0.000125	0.00208	CcSEcCtD
Sorafenib—Rash—Chenodeoxycholic acid—primary biliary cirrhosis	0.000124	0.00207	CcSEcCtD
Sorafenib—Rash—Ursodeoxycholic acid—primary biliary cirrhosis	0.000124	0.00207	CcSEcCtD
Sorafenib—Dermatitis—Ursodeoxycholic acid—primary biliary cirrhosis	0.000124	0.00206	CcSEcCtD
Sorafenib—Dermatitis—Chenodeoxycholic acid—primary biliary cirrhosis	0.000124	0.00206	CcSEcCtD
Sorafenib—Headache—Ursodeoxycholic acid—primary biliary cirrhosis	0.000123	0.00205	CcSEcCtD
Sorafenib—Headache—Chenodeoxycholic acid—primary biliary cirrhosis	0.000123	0.00205	CcSEcCtD
Sorafenib—Nausea—Chenodeoxycholic acid—primary biliary cirrhosis	0.000117	0.00195	CcSEcCtD
Sorafenib—Nausea—Ursodeoxycholic acid—primary biliary cirrhosis	0.000117	0.00195	CcSEcCtD
Sorafenib—CYP2C8—liver—primary biliary cirrhosis	0.000115	0.00333	CbGeAlD
Sorafenib—ABCG2—liver—primary biliary cirrhosis	0.000112	0.00324	CbGeAlD
Sorafenib—CYP1A2—liver—primary biliary cirrhosis	0.000108	0.00312	CbGeAlD
Sorafenib—CYP3A5—liver—primary biliary cirrhosis	0.000104	0.00301	CbGeAlD
Sorafenib—CYP2B6—liver—primary biliary cirrhosis	0.000103	0.00299	CbGeAlD
Sorafenib—CYP2C9—liver—primary biliary cirrhosis	0.000102	0.00296	CbGeAlD
Sorafenib—ABCB1—epithelium—primary biliary cirrhosis	9.74e-05	0.00282	CbGeAlD
Sorafenib—CYP3A4—liver—primary biliary cirrhosis	7.8e-05	0.00226	CbGeAlD
Sorafenib—CYP2D6—liver—primary biliary cirrhosis	7.67e-05	0.00222	CbGeAlD
Sorafenib—ABCB1—liver—primary biliary cirrhosis	5.52e-05	0.0016	CbGeAlD
Sorafenib—MKNK1—Signaling Pathways—NFKB1—primary biliary cirrhosis	3.48e-06	5.2e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—NOS2—primary biliary cirrhosis	3.43e-06	5.13e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—NOS2—primary biliary cirrhosis	3.42e-06	5.12e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—NUP210—primary biliary cirrhosis	3.41e-06	5.1e-05	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—AGT—primary biliary cirrhosis	3.39e-06	5.07e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—HIF1A—primary biliary cirrhosis	3.39e-06	5.07e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ABCB4—primary biliary cirrhosis	3.34e-06	4.99e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—DLAT—primary biliary cirrhosis	3.34e-06	4.99e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MMP3—primary biliary cirrhosis	3.34e-06	4.99e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—NUP210—primary biliary cirrhosis	3.33e-06	4.98e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—CD80—primary biliary cirrhosis	3.33e-06	4.98e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PPARGC1A—primary biliary cirrhosis	3.33e-06	4.98e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PPARGC1A—primary biliary cirrhosis	3.33e-06	4.98e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MMP3—primary biliary cirrhosis	3.33e-06	4.97e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—CD80—primary biliary cirrhosis	3.32e-06	4.97e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CCL5—primary biliary cirrhosis	3.32e-06	4.96e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CCL5—primary biliary cirrhosis	3.32e-06	4.96e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CXCL10—primary biliary cirrhosis	3.29e-06	4.91e-05	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—NFKB1—primary biliary cirrhosis	3.26e-06	4.88e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—TYK2—primary biliary cirrhosis	3.26e-06	4.87e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—CD80—primary biliary cirrhosis	3.25e-06	4.86e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—CD80—primary biliary cirrhosis	3.24e-06	4.85e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—RPS6KB1—primary biliary cirrhosis	3.21e-06	4.81e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—RPS6KB1—primary biliary cirrhosis	3.21e-06	4.81e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—TYK2—primary biliary cirrhosis	3.21e-06	4.8e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—TYK2—primary biliary cirrhosis	3.21e-06	4.8e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PPARGC1A—primary biliary cirrhosis	3.2e-06	4.79e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—GGT1—primary biliary cirrhosis	3.17e-06	4.75e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—GOT1—primary biliary cirrhosis	3.17e-06	4.75e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—CD80—primary biliary cirrhosis	3.17e-06	4.74e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—ABCG2—primary biliary cirrhosis	3.17e-06	4.74e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—MMP9—primary biliary cirrhosis	3.17e-06	4.74e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CCL5—primary biliary cirrhosis	3.15e-06	4.71e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—GOT1—primary biliary cirrhosis	3.15e-06	4.7e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—GGT1—primary biliary cirrhosis	3.15e-06	4.7e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CCL5—primary biliary cirrhosis	3.14e-06	4.69e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CXCL10—primary biliary cirrhosis	3.13e-06	4.69e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—NFKB1—primary biliary cirrhosis	3.13e-06	4.69e-05	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—NFKB1—primary biliary cirrhosis	3.13e-06	4.69e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—ABCG2—primary biliary cirrhosis	3.1e-06	4.63e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—HIF1A—primary biliary cirrhosis	3.09e-06	4.62e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—NOS2—primary biliary cirrhosis	3.09e-06	4.61e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—AGT—primary biliary cirrhosis	3.08e-06	4.61e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—AGT—primary biliary cirrhosis	3.08e-06	4.6e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—OGDH—primary biliary cirrhosis	3.08e-06	4.6e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—GGT1—primary biliary cirrhosis	3.08e-06	4.6e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—AGT—primary biliary cirrhosis	3.07e-06	4.58e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—HIF1A—primary biliary cirrhosis	3.06e-06	4.58e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—RPS6KB1—primary biliary cirrhosis	3.05e-06	4.56e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—AGT—primary biliary cirrhosis	3.05e-06	4.56e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—TYK2—primary biliary cirrhosis	3.05e-06	4.55e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—RPS6KB1—primary biliary cirrhosis	3.04e-06	4.55e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—TYK2—primary biliary cirrhosis	3.04e-06	4.54e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—HIF1A—primary biliary cirrhosis	3.02e-06	4.52e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MMP3—primary biliary cirrhosis	3e-06	4.48e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—CD80—primary biliary cirrhosis	2.99e-06	4.48e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—TYK2—primary biliary cirrhosis	2.96e-06	4.43e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CXCL10—primary biliary cirrhosis	2.93e-06	4.38e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CD80—primary biliary cirrhosis	2.89e-06	4.32e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—NUP210—primary biliary cirrhosis	2.89e-06	4.32e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MMP3—primary biliary cirrhosis	2.86e-06	4.27e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—TYK2—primary biliary cirrhosis	2.86e-06	4.27e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CCL5—primary biliary cirrhosis	2.83e-06	4.23e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PPARGC1A—primary biliary cirrhosis	2.82e-06	4.22e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—TYK2—primary biliary cirrhosis	2.81e-06	4.2e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—TYK2—primary biliary cirrhosis	2.81e-06	4.19e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PPARGC1A—primary biliary cirrhosis	2.8e-06	4.19e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—HIF1A—primary biliary cirrhosis	2.79e-06	4.16e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—HIF1A—primary biliary cirrhosis	2.79e-06	4.16e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—AGT—primary biliary cirrhosis	2.77e-06	4.15e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—AGT—primary biliary cirrhosis	2.77e-06	4.15e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—NFKB1—primary biliary cirrhosis	2.77e-06	4.15e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—NOS2—primary biliary cirrhosis	2.75e-06	4.11e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TYK2—primary biliary cirrhosis	2.75e-06	4.11e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PDHX—primary biliary cirrhosis	2.74e-06	4.1e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—RPS6KB1—primary biliary cirrhosis	2.74e-06	4.1e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PPARGC1A—primary biliary cirrhosis	2.74e-06	4.09e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—TYK2—primary biliary cirrhosis	2.74e-06	4.09e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—AGT—primary biliary cirrhosis	2.74e-06	4.09e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CD80—primary biliary cirrhosis	2.73e-06	4.08e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—CTGF—primary biliary cirrhosis	2.72e-06	4.07e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CD80—primary biliary cirrhosis	2.7e-06	4.04e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CCL5—primary biliary cirrhosis	2.7e-06	4.03e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—GOT2—primary biliary cirrhosis	2.7e-06	4.03e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ABCG2—primary biliary cirrhosis	2.68e-06	4.01e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TYK2—primary biliary cirrhosis	2.68e-06	4e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MMP3—primary biliary cirrhosis	2.67e-06	3.99e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—TYK2—primary biliary cirrhosis	2.67e-06	3.99e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—CD80—primary biliary cirrhosis	2.67e-06	3.99e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—CTGF—primary biliary cirrhosis	2.66e-06	3.97e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—HIF1A—primary biliary cirrhosis	2.64e-06	3.95e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—HIF1A—primary biliary cirrhosis	2.64e-06	3.94e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—GOT2—primary biliary cirrhosis	2.63e-06	3.94e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—AGT—primary biliary cirrhosis	2.63e-06	3.94e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—AGT—primary biliary cirrhosis	2.63e-06	3.93e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—RPS6KB1—primary biliary cirrhosis	2.61e-06	3.91e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—AGT—primary biliary cirrhosis	2.59e-06	3.88e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—AGT—primary biliary cirrhosis	2.59e-06	3.88e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ABCB4—primary biliary cirrhosis	2.58e-06	3.85e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—DLAT—primary biliary cirrhosis	2.58e-06	3.85e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—NUP210—primary biliary cirrhosis	2.58e-06	3.85e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CXCL10—primary biliary cirrhosis	2.53e-06	3.78e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—TYK2—primary biliary cirrhosis	2.53e-06	3.78e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CCL5—primary biliary cirrhosis	2.52e-06	3.77e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—NUP210—primary biliary cirrhosis	2.52e-06	3.76e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—NFKB1—primary biliary cirrhosis	2.5e-06	3.74e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—NFKB1—primary biliary cirrhosis	2.5e-06	3.74e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—AGT—primary biliary cirrhosis	2.5e-06	3.73e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CD80—primary biliary cirrhosis	2.46e-06	3.68e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CD80—primary biliary cirrhosis	2.46e-06	3.68e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—RPS6KB1—primary biliary cirrhosis	2.44e-06	3.65e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—TYK2—primary biliary cirrhosis	2.44e-06	3.65e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ABCG2—primary biliary cirrhosis	2.4e-06	3.58e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—HIF1A—primary biliary cirrhosis	2.38e-06	3.55e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—NFKB1—primary biliary cirrhosis	2.37e-06	3.55e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—NUP210—primary biliary cirrhosis	2.37e-06	3.54e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—NFKB1—primary biliary cirrhosis	2.37e-06	3.54e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—AGT—primary biliary cirrhosis	2.37e-06	3.54e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—primary biliary cirrhosis	2.35e-06	3.52e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—NUP210—primary biliary cirrhosis	2.35e-06	3.51e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ABCG2—primary biliary cirrhosis	2.34e-06	3.5e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CD80—primary biliary cirrhosis	2.33e-06	3.49e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CD80—primary biliary cirrhosis	2.33e-06	3.48e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—GOT1—primary biliary cirrhosis	2.33e-06	3.48e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—GGT1—primary biliary cirrhosis	2.33e-06	3.48e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MMP3—primary biliary cirrhosis	2.31e-06	3.45e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—TYK2—primary biliary cirrhosis	2.3e-06	3.45e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CTGF—primary biliary cirrhosis	2.3e-06	3.44e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TYK2—primary biliary cirrhosis	2.3e-06	3.44e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—GOT2—primary biliary cirrhosis	2.28e-06	3.41e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TYK2—primary biliary cirrhosis	2.28e-06	3.41e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—GOT1—primary biliary cirrhosis	2.27e-06	3.4e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—GGT1—primary biliary cirrhosis	2.27e-06	3.4e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—HIF1A—primary biliary cirrhosis	2.27e-06	3.39e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—AGT—primary biliary cirrhosis	2.26e-06	3.37e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—TYK2—primary biliary cirrhosis	2.25e-06	3.37e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ABCG2—primary biliary cirrhosis	2.2e-06	3.29e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—AGT—primary biliary cirrhosis	2.2e-06	3.29e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ABCG2—primary biliary cirrhosis	2.18e-06	3.27e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—AGT—primary biliary cirrhosis	2.18e-06	3.26e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCL5—primary biliary cirrhosis	2.18e-06	3.25e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—MMP9—primary biliary cirrhosis	2.16e-06	3.23e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—NFKB1—primary biliary cirrhosis	2.14e-06	3.2e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—NFKB1—primary biliary cirrhosis	2.13e-06	3.19e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—AGT—primary biliary cirrhosis	2.13e-06	3.19e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—HIF1A—primary biliary cirrhosis	2.12e-06	3.17e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—RPS6KB1—primary biliary cirrhosis	2.11e-06	3.15e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—AGT—primary biliary cirrhosis	2.11e-06	3.15e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—MMP9—primary biliary cirrhosis	2.11e-06	3.15e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—primary biliary cirrhosis	2.1e-06	3.14e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CD80—primary biliary cirrhosis	2.1e-06	3.13e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—NFKB1—primary biliary cirrhosis	2.09e-06	3.12e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TYK2—primary biliary cirrhosis	2.08e-06	3.1e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TYK2—primary biliary cirrhosis	2.08e-06	3.1e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PPARGC1A—primary biliary cirrhosis	2.07e-06	3.1e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CTGF—primary biliary cirrhosis	2.06e-06	3.07e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GOT2—primary biliary cirrhosis	2.04e-06	3.05e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PPARGC1A—primary biliary cirrhosis	2.02e-06	3.03e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—NUP210—primary biliary cirrhosis	2.01e-06	3e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CTGF—primary biliary cirrhosis	2.01e-06	3e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CD80—primary biliary cirrhosis	2e-06	2.99e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—ALB—primary biliary cirrhosis	1.99e-06	2.98e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—ALB—primary biliary cirrhosis	1.99e-06	2.98e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GOT2—primary biliary cirrhosis	1.99e-06	2.97e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—GGT1—primary biliary cirrhosis	1.97e-06	2.95e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—GOT1—primary biliary cirrhosis	1.97e-06	2.95e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TYK2—primary biliary cirrhosis	1.97e-06	2.94e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TYK2—primary biliary cirrhosis	1.96e-06	2.94e-05	CbGpPWpGaD
Sorafenib—ABCB1—Transmembrane transport of small molecules—ALB—primary biliary cirrhosis	1.95e-06	2.91e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—primary biliary cirrhosis	1.91e-06	2.86e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—NFKB1—primary biliary cirrhosis	1.9e-06	2.84e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CTGF—primary biliary cirrhosis	1.89e-06	2.83e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CTGF—primary biliary cirrhosis	1.87e-06	2.8e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GOT2—primary biliary cirrhosis	1.87e-06	2.8e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CD80—primary biliary cirrhosis	1.87e-06	2.79e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ABCG2—primary biliary cirrhosis	1.87e-06	2.79e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GOT2—primary biliary cirrhosis	1.86e-06	2.78e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—HIF1A—primary biliary cirrhosis	1.83e-06	2.73e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—AGT—primary biliary cirrhosis	1.82e-06	2.72e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—MMP9—primary biliary cirrhosis	1.81e-06	2.71e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—MMP9—primary biliary cirrhosis	1.8e-06	2.68e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—NFKB1—primary biliary cirrhosis	1.79e-06	2.68e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—NFKB1—primary biliary cirrhosis	1.78e-06	2.66e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TYK2—primary biliary cirrhosis	1.77e-06	2.65e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GGT1—primary biliary cirrhosis	1.76e-06	2.63e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GOT1—primary biliary cirrhosis	1.76e-06	2.63e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PPARGC1A—primary biliary cirrhosis	1.75e-06	2.62e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GOT1—primary biliary cirrhosis	1.72e-06	2.57e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GGT1—primary biliary cirrhosis	1.72e-06	2.57e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—ALB—primary biliary cirrhosis	1.69e-06	2.52e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TYK2—primary biliary cirrhosis	1.69e-06	2.52e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—ALB—primary biliary cirrhosis	1.67e-06	2.5e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—primary biliary cirrhosis	1.64e-06	2.45e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MMP9—primary biliary cirrhosis	1.63e-06	2.44e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MMP9—primary biliary cirrhosis	1.63e-06	2.44e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GGT1—primary biliary cirrhosis	1.62e-06	2.42e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GOT1—primary biliary cirrhosis	1.62e-06	2.42e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—NFKB1—primary biliary cirrhosis	1.62e-06	2.42e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—NFKB1—primary biliary cirrhosis	1.62e-06	2.42e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CD80—primary biliary cirrhosis	1.61e-06	2.41e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—AGT—primary biliary cirrhosis	1.61e-06	2.41e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GOT1—primary biliary cirrhosis	1.6e-06	2.4e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GGT1—primary biliary cirrhosis	1.6e-06	2.4e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CTGF—primary biliary cirrhosis	1.6e-06	2.39e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GOT2—primary biliary cirrhosis	1.59e-06	2.37e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TYK2—primary biliary cirrhosis	1.58e-06	2.36e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—AGT—primary biliary cirrhosis	1.58e-06	2.36e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PPARGC1A—primary biliary cirrhosis	1.56e-06	2.34e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MMP9—primary biliary cirrhosis	1.55e-06	2.32e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—NUP210—primary biliary cirrhosis	1.55e-06	2.32e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MMP9—primary biliary cirrhosis	1.55e-06	2.31e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—NFKB1—primary biliary cirrhosis	1.53e-06	2.29e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—NFKB1—primary biliary cirrhosis	1.53e-06	2.29e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PPARGC1A—primary biliary cirrhosis	1.53e-06	2.28e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ABCG2—primary biliary cirrhosis	1.44e-06	2.15e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PPARGC1A—primary biliary cirrhosis	1.44e-06	2.15e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PPARGC1A—primary biliary cirrhosis	1.43e-06	2.13e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MMP9—primary biliary cirrhosis	1.39e-06	2.08e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—NFKB1—primary biliary cirrhosis	1.38e-06	2.06e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GOT1—primary biliary cirrhosis	1.37e-06	2.05e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GGT1—primary biliary cirrhosis	1.37e-06	2.05e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—AGT—primary biliary cirrhosis	1.37e-06	2.04e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TYK2—primary biliary cirrhosis	1.36e-06	2.04e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MMP9—primary biliary cirrhosis	1.33e-06	1.99e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NFKB1—primary biliary cirrhosis	1.31e-06	1.97e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MMP9—primary biliary cirrhosis	1.24e-06	1.86e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—ALB—primary biliary cirrhosis	1.24e-06	1.85e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CTGF—primary biliary cirrhosis	1.24e-06	1.85e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NFKB1—primary biliary cirrhosis	1.23e-06	1.84e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GOT2—primary biliary cirrhosis	1.22e-06	1.83e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PPARGC1A—primary biliary cirrhosis	1.22e-06	1.82e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—AGT—primary biliary cirrhosis	1.22e-06	1.82e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—ALB—primary biliary cirrhosis	1.21e-06	1.81e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—AGT—primary biliary cirrhosis	1.19e-06	1.78e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—AGT—primary biliary cirrhosis	1.12e-06	1.68e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—AGT—primary biliary cirrhosis	1.11e-06	1.66e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MMP9—primary biliary cirrhosis	1.07e-06	1.6e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NFKB1—primary biliary cirrhosis	1.06e-06	1.59e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GGT1—primary biliary cirrhosis	1.06e-06	1.58e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GOT1—primary biliary cirrhosis	1.06e-06	1.58e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ALB—primary biliary cirrhosis	1.05e-06	1.57e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—AGT—primary biliary cirrhosis	9.5e-07	1.42e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PPARGC1A—primary biliary cirrhosis	9.41e-07	1.41e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ALB—primary biliary cirrhosis	9.35e-07	1.4e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ALB—primary biliary cirrhosis	9.13e-07	1.36e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ALB—primary biliary cirrhosis	8.6e-07	1.29e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ALB—primary biliary cirrhosis	8.53e-07	1.28e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—AGT—primary biliary cirrhosis	7.33e-07	1.1e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ALB—primary biliary cirrhosis	7.29e-07	1.09e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ALB—primary biliary cirrhosis	5.62e-07	8.41e-06	CbGpPWpGaD
